XML 17 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 15, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2023    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-36296    
Entity Registrant Name Carisma Therapeutics Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 26-2025616    
Entity Address, Address Line One 3675 Market Street    
Entity Address, Address Line Two Suite 200    
Entity Address, City or Town Philadelphia    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19104    
City Area Code 267    
Local Phone Number 491-6422    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol CARM    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 275,726,423
Entity Common Stock, Shares Outstanding   41,542,534  
Documents Incorporated by Reference
The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2023. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.
    
Entity Central Index Key 0001485003    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY